News & Updates

Adagrasib shows antitumour activity in KRAS G12C-mutant colorectal cancer
Adagrasib shows antitumour activity in KRAS G12C-mutant colorectal cancer
07 Jan 2023

Adagrasib appears to have some effect against metastatic, KRAS G12C-mutated colorectal cancer when used in treatment-experienced patients either as oral monotherapy or in combination with cetuximab, according to the results of a phase I-II, open-label study.

Adagrasib shows antitumour activity in KRAS G12C-mutant colorectal cancer
07 Jan 2023
Cardiovascular, mortality outcomes in hypertension similar between two thiazide diuretics
Cardiovascular, mortality outcomes in hypertension similar between two thiazide diuretics
06 Jan 2023

The use of chlorthalidone in the treatment of patients with hypertension does not appear to provide better protection against major cardiovascular outcome events or noncancer-related deaths when compared with hydrochlorothiazide, according to a study.

Cardiovascular, mortality outcomes in hypertension similar between two thiazide diuretics
06 Jan 2023
Age does not affect palbociclib dose reduction, discontinuation in breast cancer patients
Age does not affect palbociclib dose reduction, discontinuation in breast cancer patients
06 Jan 2023

The age of patients with advanced breast cancer appears to have no influence on the rate of palbociclib dose reductions or discontinuations secondary to neutropaenia, a study has shown.

Age does not affect palbociclib dose reduction, discontinuation in breast cancer patients
06 Jan 2023
Can breast cancer survivors temporarily stop endocrine therapy to attempt pregnancy?
Can breast cancer survivors temporarily stop endocrine therapy to attempt pregnancy?
05 Jan 2023 byRoshini Claire Anthony

Young breast cancer survivors could safely temporarily stop adjuvant endocrine therapy (ET) to attempt pregnancy, according to primary results of the POSITIVE* trial presented at SABCS 2022.

Can breast cancer survivors temporarily stop endocrine therapy to attempt pregnancy?
05 Jan 2023
5α-reductase inhibitor treatment implicated in dementia
5α-reductase inhibitor treatment implicated in dementia
05 Jan 2023

Men who are receiving treatment with 5α-reductase inhibitors (5-ARIs) are at increased risk of dementia in the immediate period after initiating treatment, a study has shown. Of note, both finasteride and dutasteride are associated with depression, but neither of them is linked to suicide.

5α-reductase inhibitor treatment implicated in dementia
05 Jan 2023
Edoxaban prevents thromboembolism in children with cardiac disease
Edoxaban prevents thromboembolism in children with cardiac disease
04 Jan 2023

Edoxaban may be used as an alternative treatment for thromboembolism (TE) prevention in children with cardiac disease showing low rates of clinically relevant bleeding and TE, suggests a study. Some of its advantages include once-daily dosing and infrequent monitoring requirement.

Edoxaban prevents thromboembolism in children with cardiac disease
04 Jan 2023